Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project.

[1]  M. Hall.  National Heart, Lung, and Blood Institute , 2020, The Grants Register 2021.

[2]  Robert C. Green,et al.  Reconciling newborn screening and a novel splice variant in BTD associated with partial biotinidase deficiency: a BabySeq Project case report , 2018, Cold Spring Harbor molecular case studies.

[3]  R. Green,et al.  The BabySeq project: implementing genomic sequencing in newborns , 2018, BMC Pediatrics.

[4]  E. Parens,et al.  Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies. , 2018, The Hastings Center report.

[5]  R. Green,et al.  Parental Interest in Genomic Sequencing of Newborns: Enrollment Experience from the BabySeq Project , 2018, Genetics in Medicine.

[6]  Fan Xia,et al.  Use of Exome Sequencing for Infants in Intensive Care Units: Ascertainment of Severe Single-Gene Disorders and Effect on Medical Management , 2017, JAMA pediatrics.

[7]  Laurie D. Smith,et al.  The NSIGHT1-randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants , 2017, npj Genomic Medicine.

[8]  Lorenzo D Botto,et al.  Etiology and clinical presentation of birth defects: population based study , 2017, British Medical Journal.

[9]  R. Knöll,et al.  Genetic epidemiology of titin-truncating variants in the etiology of dilated cardiomyopathy , 2017, Biophysical Reviews.

[10]  Tiina K. Urv,et al.  Newborn Sequencing in Genomic Medicine and Public Health , 2017, Pediatrics.

[11]  H. Win,et al.  Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens , 2017, PLoS medicine.

[12]  Matthew S. Lebo,et al.  A curated gene list for reporting results of newborn genomic sequencing , 2017, Genetics in Medicine.

[13]  R. Płoski,et al.  Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations , 2017, PloS one.

[14]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[15]  T. Pal,et al.  BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer , 2016 .

[16]  J. Clayton-Smith,et al.  Clinical and genetic aspects of KBG syndrome , 2016, American Journal of Medical Genetics. Part A.

[17]  J. Koskenvuo,et al.  Relevance of truncating titin mutations in dilated cardiomyopathy , 2016, Clinical genetics.

[18]  J. Koskenvuo,et al.  Prevalence of Titin Truncating Variants in General Population , 2015, PLoS ONE.

[19]  S. Kingsmore.  Newborn testing and screening by whole-genome sequencing , 2015, Genetics in Medicine.

[20]  Chad A Shaw,et al.  Molecular Diagnostic Experience of Whole-Exome Sequencing in Adult Patients , 2015, Genetics in Medicine.

[21]  R. Green,et al.  Disclosing Secondary Findings from Pediatric Sequencing to Families: Considering the “Benefit to Families” , 2015, Journal of Law, Medicine & Ethics.

[22]  P. Ghiringhelli,et al.  Misregulation effect of a novel allelic variant in the Z promoter region found in cis with the CYP21A2 p.P482S mutation: implications for 21-hydroxylase deficiency , 2015, Endocrine.

[23]  Jonathan S Berg,et al.  Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. , 2015, American journal of human genetics.

[24]  J. Lupski,et al.  Secondary findings and carrier test frequencies in a large multiethnic sample , 2015, Genome Medicine.

[25]  D. Bailey,et al.  Newborn screening: evolving challenges in an era of rapid discovery. , 2015, JAMA.

[26]  S. Livadas,et al.  The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene , 2015, Clinical endocrinology.

[27]  Tan Ru San,et al.  Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease , 2015, Science Translational Medicine.

[28]  Matthew S. Lebo,et al.  A systematic approach to the reporting of medically relevant findings from whole genome sequencing , 2014, BMC Medical Genetics.

[29]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[30]  W. Chung,et al.  Complex genetics and the etiology of human congenital heart disease. , 2014, Cold Spring Harbor perspectives in medicine.

[31]  Heidi L Rehm,et al.  American College of Medical Genetics and Genomics guideline for the clinical evaluation and etiologic diagnosis of hearing loss , 2014, Genetics in Medicine.

[32]  Sivakumar Gowrisankar,et al.  The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing , 2014, Genetics in Medicine.

[33]  Trevor J Pugh,et al.  A systematic approach to assessing the clinical significance of genetic variants , 2013, Clinical genetics.

[34]  Emily H Turner,et al.  Actionable, pathogenic incidental findings in 1,000 participants' exomes. , 2013, American journal of human genetics.

[35]  Nasim Vasli,et al.  Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy , 2013, Neurology.

[36]  I. Bottillo,et al.  Prenatal diagnosis and post-mortem examination in a fetus with thrombocytopenia-absent radius (TAR) syndrome due to compound heterozygosity for a 1q21.1 microdeletion and a RBM8A hypomorphic allele: a case report , 2013, BMC Research Notes.

[37]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[38]  H. Kojima,et al.  Comprehensive Genetic Screening of KCNQ4 in a Large Autosomal Dominant Nonsyndromic Hearing Loss Cohort: Genotype-Phenotype Correlations and a Founder Mutation , 2013, PloS one.

[39]  J. Mulliken,et al.  Genotypes and Phenotypes of 162 Families with a Glomulin Mutation , 2013, Molecular Syndromology.

[40]  H. Saal,et al.  Ethical and Policy Issues in Genetic Testing and Screening of Children , 2013, Pediatrics.

[41]  J. Seidman,et al.  Genetics of congenital heart disease: the glass half empty. , 2013, Circulation research.

[42]  W. Treem.  Clinical Aspects and Treatment of Congenital Sucrase-Isomaltase Deficiency , 2012, Journal of pediatric gastroenterology and nutrition.

[43]  Balaji S. Srinivasan,et al.  An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals , 2012, Genetics in Medicine.

[44]  Ana Cvejic,et al.  Inheritance of low-frequency regulatory SNPs and a rare null mutation in exon-junction complex subunit RBM8A causes TAR , 2012, Nature Genetics.

[45]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[46]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[47]  Mustafa Tekin,et al.  Mutations in ANKRD11 cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. , 2011, American journal of human genetics.

[48]  A. Pinchera,et al.  Identification and functional analysis of novel dual oxidase 2 (DUOX2) mutations in children with congenital or subclinical hypothyroidism. , 2011, The Journal of clinical endocrinology and metabolism.

[49]  N. McDonnell,et al.  Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2011, The Journal of clinical endocrinology and metabolism.

[50]  P. Patsalis,et al.  Molecular Defects of the CYP21A2 Gene in Greek-Cypriot Patients with Congenital Adrenal Hyperplasia , 2010, Hormone Research in Paediatrics.

[51]  R. Houlston,et al.  Clinical implications of the colorectal cancer risk associated with MUTYH mutation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  David Reich,et al.  A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia , 2009, Nature Genetics.

[53]  S. Berger,et al.  Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and , 2008, Circulation.

[54]  Maria I New,et al.  Extensive clinical experience: nonclassical 21-hydroxylase deficiency. , 2006, The Journal of clinical endocrinology and metabolism.

[55]  T. Battelino,et al.  Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. , 2005, European journal of endocrinology.

[56]  R. Hershberger,et al.  Clinical and genetic issues in familial dilated cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[57]  S. Lajic,et al.  Functional analysis of two recurrent amino acid substitutions in the CYP21 gene from Italian patients with congenital adrenal hyperplasia. , 2004, The Journal of clinical endocrinology and metabolism.

[58]  Pamela J. McCabe,et al.  American Heart Association Council on cardiovascular nursing. , 2004 .

[59]  F. Baas,et al.  Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. , 2002, The New England journal of medicine.

[60]  M. D'urso,et al.  The ABCA4 2588G>C Stargardt mutation: single origin and increasing frequency from South-West to North-East Europe , 2002, European Journal of Human Genetics.

[61]  John Atherton,et al.  Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy , 2002, Nature Genetics.

[62]  C. Stanley,et al.  Mutations in BTD causing biotinidase deficiency , 2001, Human mutation.

[63]  Balsamo,et al.  CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia–Romagna region , 2000, Clinical endocrinology.

[64]  K. Schulpis,et al.  Glucose-6-phosphate dehydrogenase deficiency neonatal screening: preliminary evidence that a high percentage of partially deficient female neonates are missed during routine screening , 2000, Journal of medical screening.

[65]  V. Stigliano,et al.  Lynch Syndrome: Molecular Mechanism and Current Clinical Practice , 2018, Constitutional Oncogenetics.

[66]  D. Goldfarb,et al.  Early Recognition and Management of Rare Kidney Stone Disorders. , 2017, Urologic nursing.

[67]  D. Kavanagh,et al.  Atypical haemolytic uraemic syndrome. , 2006, British medical bulletin.

[68]  Ose,et al.  Inactivating mutations in the gene for thyroid oxidase 2 ( THOX 2 ) and congenital hypothyroidism , 2002 .

[69]  G. Buck,et al.  Double mutation (A171T) and (D444H) is a common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States , 1998 .

[70]  E. Beutler.  G6PD deficiency. , 1994, Blood.

[71]  B. Lyons,et al.  Hemophilia A. , 1969, Oral surgery, oral medicine, and oral pathology.